x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

COR2ED - Oncology Medical Conversation

COR2ED Medical Education

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit

science courses

All Episodes

00:25:03

Metastatic breast cancer: Understanding HER2-low and...

COR2ED - Oncology Medical Conversation ·

2025/12/17

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice. The experts explore: Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework The clinical relevance of HER2-low and HER2-ultralow categories, and

en

00:27:28

Understanding EP-NEC: Through Diagnosis, Treatment,...

COR2ED - Oncology Medical Conversation ·

2025/11/07

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers. They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches,

en

00:27:28

Understanding EP-NEC: Through Diagnosis, Treatment,...

COR2ED - Oncology Medical Conversation ·

2025/11/07

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers. They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches,

en

00:21:56

Exploring the role of targeted radiopharmaceutical...

COR2ED - Oncology Medical Conversation ·

2025/09/30

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety? In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in

en

00:21:56

Exploring the role of targeted radiopharmaceutical...

COR2ED - Oncology Medical Conversation ·

2025/09/30

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety? In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in

en

00:21:32

Exploring the role of targeted radiopharmaceutical...

COR2ED - Oncology Medical Conversation ·

2025/09/17

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety? In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in

en

00:21:51

Tackling mPDAC: chemotherapy strategies that matter

COR2ED - Oncology Medical Conversation ·

2025/05/19

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved. This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the

en

00:21:51

Tackling mPDAC: chemotherapy strategies that matter

COR2ED - Oncology Medical Conversation ·

2025/05/19

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved. This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the

en

00:20:34

Understanding Rare NSCLC Mutations: Insights, access...

COR2ED - Oncology Medical Conversation ·

2025/05/14

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK. As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari. Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker

en

00:20:34

Understanding Rare NSCLC Mutations: Insights, access...

COR2ED - Oncology Medical Conversation ·

2025/05/14

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK. As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari. Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker

en

00:18:36

The HER2 diagnostic and treatment landscape in NSCLC

COR2ED - Oncology Medical Conversation ·

2025/04/28

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain. In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC. The conversation unfolds to cover; How

en

00:18:36

The HER2 diagnostic and treatment landscape in NSCLC

COR2ED - Oncology Medical Conversation ·

2025/04/28

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain. In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC. The conversation unfolds to cover; How

en

00:21:27

The HER2 Diagnostic and Treatment Landscape in NSCLC

COR2ED - Oncology Medical Conversation ·

2025/04/15

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain. What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos. In

en

00:21:27

The HER2 Diagnostic and Treatment Landscape in NSCLC

COR2ED - Oncology Medical Conversation ·

2025/04/15

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain. What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos. In

en

00:13:43

ER+ metastatic breast cancer: Key insights on...

COR2ED - Oncology Medical Conversation ·

2025/03/31

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Key topics include Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET Clinical implications of the EMERALD subgroup analyses Review of elacestrant's safety

en

00:13:43

ER+ metastatic breast cancer: Key insights on...

COR2ED - Oncology Medical Conversation ·

2025/03/31

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Key topics include Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET Clinical implications of the EMERALD subgroup analyses Review of elacestrant's safety

en

00:26:05

Best practices in molecular testing and targeted...

COR2ED - Oncology Medical Conversation ·

2025/03/21

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer. Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine. Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices. Tune in for a practical,

en

00:26:05

Best practices in molecular testing and targeted...

COR2ED - Oncology Medical Conversation ·

2025/03/21

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer. Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine. Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices. Tune in for a practical, expert-led discussion on how

en

00:11:28

Advanced or recurrent endometrial cancer: Molecular...

COR2ED - Oncology Medical Conversation ·

2025/02/17

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions Key clinical takeaways: MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations Lenvatinib plus

en

00:11:28

Advanced or recurrent endometrial cancer: Molecular...

COR2ED - Oncology Medical Conversation ·

2025/02/17

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions Key clinical takeaways: MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations Lenvatinib plus

en

181 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter